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1V 
工NTRODUCTION
Recen七1y，much effort has been centered in increasing七he
effec七ivenessand decreasing side-effec七sof drug.s in七herapy.
On that standpoint， a number of drug delivery systems have been 
designed and examined七oimprove drug therapy over七ha七 achieved
1-19) with conventional preparations 
An effective七herapyis better achieved by七heat七ainzIlexI七
of the appropriate concentration of drug at七hepar七icu1ar七arget
site within the body for a desired duration. ~fuen a drug is 
administered to a patient， it must be七ransportedfrom the site 
of administration to a target site. Therefore，七heroute of 
administration as well as七hedose of drug becomes important 
factor in governing七herapeuticactions. 
Some typical examp1es are schematica11y shown in Fig. 1， a. 
The ordinate shows drug level in plasma or corresponding drug 
1evel in par七icular七issue. When a drug is administered intra-
veneously， ora11y， or intramuscu1ar1y， drug leve1 decreases 
exponentia11y wi七htime after its peak 1evel. Administra七ion
of large doses， although drug levels can be main七ainedin the 
therapeutic range for 10nger periods of time， may result in a 
toxic effect. Repea七eddosing has been adop七ed七oachieve longer 
duration of drug action (Fig. 1， b). As is apparent in the figure， 
inadequate dosing intervals may cause insufficien七 druglevels 
(because of too 10ng intervals) or toxic reactions (too short 
interv.als). Patient compliance with the dosing regimen may limit 
七hesuccess in the repeated dosing therapy. 
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An idea1 drug delivery sys七emmay be described as follows: 
七hesystem contains and releases a minimum amoun七 ofdrug suffi-
cien七 tomain七ainthe七herapeuticac七ionat the target for a 
desired period of七ime (Fig. 1， c). Thus， incidences of side 
reactions， concentration-dependent or si七e-dependent，could a1so 
be minimized. Such an ideal system has not yet been prepared 
and fur七herdevelopment is desired. 
A contro11ed-re1ease formu1ation or de1ivery system contains 
drug in polymeric material and can a110w drug delivery to七he
target organ at controlled rates over a specified period. One 
????????????????????? ??????。???。??????????? ???? ????????????????
with the drug in a fluid. The role of membrane in controlling 
the release rate of drug is wel1 known. Since permeation is a 
three-step process of partition in七0，diffusion through， and 
partition out of the membrane， the permeation ra七eof drug depends 
on the nature of the membrane materia1s as we11 as the thickness 
and area of the membrane. Thus， the choice of membrane materia1s 
20，21) is important-Vr 
Besides七hemembrane， the design of the drug reservoir can 
inf1uence the drug release characteristics. If simple solutions 
of drug are enclosed within the membrane， the drug permeation 
rate declines rapidly unless the reservoir volume is large. 
In order to design the reservoir with a limi七edvolume but of 
large sustaining capaci七y，suspensions have been employed as the 
22) reservoir system~~/. Since suspensions have their own problems 
such as sedimentation and particle-size growth of ~he dispersed 
drug during storage which may cause an unprogrammable release 
4 
rate of drug， a reservoir in七heform of a solu七ionis some七imes
preferred. 
工nthis work， pO$sible uses of complexes， micel1es， cosolven七s，
and emulsions in sustaining the release of drug were proposed. 
By using these systems，七hedrug can be introduced in a solubilized 
form. The func七ionalityof each system as a reservoir was examined. 
工tis repor七edtha七， inpa七ientswith advanced cancer， pain 
23) becomes their main complaint during their las七 yearof life 
Once causal treatmen七 isno longer able to cure七hepatient，七he
main goal of fur七hertherapy is七hecomfort of the patient. 
In order to relieve these patients from unbearable pain， 
local anesthetics are often adminis七ered. 工nthis work， means 
of controlling release of local anes七heticsare examined because 
of grea七 demandof achieving an extended period of anesthetic 
action from clinicians operating pain clinics. The present 
approaches can however be ex七endedto controlled release of other 
therapeutic agents such as steroids and an七icanceragents. 
THEORETICAL CONS工DERAT工ONS
(WITH LITERATURE REVIEW) 
22，24) 1. Drug Re1ease through Po1ymer Membranes and Polymer Matrices 
When the transfer of drug七hrougha po1ymer rnembrane frorn 
a donor so1u七ion七oa receptor so1u七ionis considered， Fick's 
1aw of diffusion can be resta七ed:
(Eq. 1) 
where dMr/dt = release rate， D = diffusivity in the membrane， 
A = surface area of the membrane， and dCm/dx = concentration 
gradien七 in七hemembrane. 
In 七hes七eadystate， Eq. 1 may be wri七七en:
Cm，d -Cm，r = DA F dt _4~ f
kdCd -KrCr 
DAd (Eq. 2) 
where Cm，d and Cm，r = drug concen七ra七ionsin the rnembrane a七 the
donor side and recep七orside， respec七ivelYi Kd and Kr = dis七ribu-
七ioncoefficients of七hedrug between七hemembrane and donor 
solution and七hemembrane and the recep七orsolution， respectivelYi 
Cd and Cr = drug concentrations in七hedonor solution and the 
recep七orsolu七ion，respec七ivelYi and 1 =七hicknessof七hemembrane. 
工fa sink condition is maintained in七herecep七orsolution， 
Cr remains negligible compared七oCd. Then Eq. 2 can be 
simplified七0:
DAKd _. AP 
Cd =ヲー Cd (Eq. 3) 
where P = Dkd = perrneability. 
5 
6 
When an undersa七ura七eddrug s01u七ion (or a sa七ura七eddrug 
solution without excess solid phase) is placed in七hedonor 
compartment， the drug concentration in the donor solution 
decreases with七imeas七hedrug permea七es七0 七hereceptor solution 
(Fig. 2， a). Under this condition， Eq. 3 becomes: 
dMr AP_i 
dt =ヲ:.-Cd exp (-AP七/1V) (Eq. 4) 
l where V = volume of the donor solution and C: = ini七ialconcen-d 
tration of drug in七hedonor solu七ion. Thus， the re1ease ra七e
???????????????????????????????
When a drug is dispersed as a solid in a po1ymer matrix 
.25) 
(Fig. 2， b)， the release equation has been derived by T. Higuchi 
|芋塩dMr =一A (2C-C ) dt -21 t \~\..ø O - ¥.os 
2DC3c必
N A lo| 》 mi-I t ~ I for Co)> c; 
(Eq. 5) 
(Eq. 6) 
where c:=ω1ubili七yof drug in the polymer phase and Co = t。ω
concen七rationof drug in the ma七rix (dissolved p1us dispersed). 
¥、 mThe assumption七hatCo方>C: is reasonable for polymer-drug " s 
dispersions containing more七hail5 wtも drug，but i七 isoften valid 
22) 
for polymer-drug dispersions containing as li七七leas 1 wtも drug 
From Eq. 5 it follows that the release rate is inversely propor-
七ionalto七hesquare roo七 of七ime，meaning tha七七herelease rate 
decreases with time. 
In order to achieve constant release from a drugdelivery 
system， the concentration gradient has to be rnaintained constant. 
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A constant concentra七iongradient rnay be achieved by having 
26) 
either: a) a large volume reservoir of drug in七hesolu七ion
22) 
or b) the drug in七hesolid phase ~ in七hedonor side of a rnernbrane 
and a sink condition in七herecep七orside. Because of the 
difficulty in accornodating a large volume reservoir wi七hin七he
drug delivery systern， suspensions are usua11y employed七omain-
tain the drug concen七ra七ionwi七hin七hede1ivery sys七emcons七an七.
When a suspension is placed a七 thedonor side (Fig. 2， c and 
Fig. 3， a)，七hedrug concentra七ionin the donor solu七ionremains 
constan七 because10S9 of drug frorn the s01u七ionby permea七ionis 
constantly cornpensa七edfor by七hediss01u七ionof 901id drug. 
Eq. 3 is then wri七七en:
dMr AP_ 
dt = i (，;9 (Eq. 7) 
where Cs = solubility of七hedrug in the donor 901u七ion. Since 
all terrns on the right-hand side of Eq. 7 are constan七， the 
release rate of drug through the'membrane is cons七an七.
When a drug-dispersed rnatrix is laminated by a polymer 
rnembrane with smaller permeability， a core rnatrix serves as a 
reservoir for the release. Constant release ra七esof drugs have 
27) 
been obtained by such lamina七ion
A new approach七oobtain constant-rate release of drug frorn 
28，29) drug-dispersed ma七rixwas described~U ， ~J'. The systern， having 
an unique qeome七ry，was theore七icallyanalyzed and experimentally 
七estedfor its drug-releasing behavior. This principle was also 
app1icab1e to release of drug from the solid drug. 
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24，30) 
2. Systems Containing Soluble Complexes-.' 
Complexation in pharmaceutical systems has been studied by 
311 many workers~~J. Its possible role in accelerating or retarding 
drug permeation through a si1icone membrane has been reported 
32，33) 
• When a drug solu七ioncontaining a complexing agent is 
placed in七hedonor compartment，七hecomplexed drug may serve as 
a reservoir (Fig. 3， b). Loss of uncomplexed (permeable) drug 
from the donor solu七ionby permeation is par七lycompensa七edfor 
by dissocia七ionof七hecomplex. Therefore， the concentration of 
permeable drug does not decrease as rapidly as in七heplain 
solution (Fig. 2， a). 
When the fraction of complexed drug is large，七heconcen-
tra七ionof permeable drug may be kept fairly constan七 andthe 
?????
?
????
?
???
?
???????。????
????
???????
?
?? ??????????? ????
?
?????
。 ?
????????
diffusion process in the membrane. Therefore， the fol1owing 
assumptions seem to be reasonable七hatan equilibra七ionbe七ween
七hefree drugs and complexes is established at any moment and 
that diffusion in the membrane is a rate-limi七ingprocess in the 
drug release. 
In the present s七udies，七heeffects of七hreetypes of 
complexes on the permeation of a local anesthe七icwere investigated. 
The complexes included were: a) plane七oplane， b) inclusion， and 
c) macromolecular complexes. Caffeine has been reported七oform 
cornplexes with aromatic molecules， presumably of plane-to-plane 
36-38) 
S七acking----'.α-and s-Cyclodex七rins，on the other hand， have 
39-43) 
been known to include drug molecules within their cavi七ies
its to studied been has 
11 
polymer， water-soluble a Povidone， as 
7・(2-Hydroxyethyl)theophylline
、•• ，?
???
? ?? ???????? ???tendencies complexing 
molecules. aromatic complexes. with forrn to expected also 1S 
? ?? ?
， ， ?
?? ?
， ， ??、?????????Containing Sys七ems3. 
??
』 、
?，
????
?
?
?
?
?
?
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七heirabove known， are solution aqueous 1n Surfac七ants
can drug 七hewhich 1n七。rnicelles forrn to concentra七ions，
back par七l七10ncan 七urn，1n micelles， the ェnsolubi1ized drug The 
bulk 七heエnconcen七rationdrug 七hewhen solution bulk 七heinto 
b) . 3， (Fig. mernbrane a 七hroughpermeation 七。due decreased lS phase 
Recep七orDonor 
Sink Vw，Cw 
release sustained of 
Membrane 
represen七a七ionSchema七ic
??
Flgure 
model) • (proposed micelles containing system a frorn of drug 
lS 4 Fig. 1n shown model simple following the system， 七hisFor 
dis七ribu七edlS drug the compartmen七，donor 七he1n 1) considered: 
a and phase micel1ar dispersed a 1.e. phases， two the between 
can la七七erthe 1n drug 七heonly and phase aqueous con七ir1110us 
be七weendrug 七heof distribu七ion2) membrane， 七hethrough permeate 
momen七，any at instantaneous lS phases aqueous and micellar the 
membrane the a七effect layer diffusion 七heof contribution 3) and 
neglected. be can surface 
these between drug the of Kp coefficient， distribu七ionThe 
by: ?????lS phases two 
12 
Kp = Crn (Eq. 8) 一一Cw 
where C， M， and V denote theconcentration and the amoun七 of七he
drug in each phase， and七hevo1ume of each phase， respec七ive1y，
and the subscripts m and w indica七ea rnice11ar phase and an 
aqueous phase~ respec七ive1y. Under七heseconditions， if sink 
condi七ionsare maintained in七hereceptor side， Eq. 3 becomes: 
? ? ?
APCw 
f 
(Eq. 9) 
where Mr 七hearnoun七 ofdrug in the receptor s01u七iona七七irne七.
The tota1 amoun七 ofdrug in七hedonor solution， Mt is given by: 
M七=Mm + Mw = Moo -Mr (Eq. 10) 
where Mca =七heto七a1amoun七 ofdrug initia11y introduced into 
the sys七em. Rearrangemen七 ofEq. 8-10 1eads七0:
t. ， APt I 
Mr = MoO L1 -expJt-1 (Kp ・v~-+ Vw) J (Eq. 11) 
By definition: 
M~ = VmCmo + VwCwo 
CmO = KpCwo 
(Eq. 12) 
(Eq. 13) 
where Cmo and Cwo are七heinitia1 concentrations of drug in七he
mice11ar phase and aqueous phase， respec七ive1y. Rearrangemen七
of Eq. 11-13 1eads to Eq. 14. 
Mr =咋ー州国APC山川口o>} (Eo. 14) 
13 
where V =七hevo1ume of七hedonor so1u七ionand CtO = the七ota1
initia1 concentration of drug in七hedonor solution. The ra七io
CWO/CtO is equal七oCso/Cs at equilibrium， where Cso and Cs = 
the solubilities of drug in wa七erand a surfactan七 solu七ion，
respec七ively. Then， Eq. 14 becomes: 
Mr =叫ー吋慌の々VC (Eq. 15) 
or in rewritten form: 
?
? ????
?
?
????????
?
???? ???? (Eq. 16) 
For the sys七emwhere a drug solution is enclosed in the 
48) ho11ow cylinder， Eq. 17 has been reported 
Mr =叫-吋-21ThPt川 (Eq. 17) 
where ri and ro = inner and outer diame七ersof the cy1inder 
and h =七heleng七hof the cylinder. For the case where a drug 
solution containing mice11es， Eq. 18 was derived following the 
same manner as was done in deriving Eq. 15 from Eq. 3: 
、 ?
???
?
、 ，
?、
??
??? ???????、 ????? ????????? ? ?
??
?????
???
、
????? (Eq. 18) 
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46) 4. Systems Consisted of Cosolvents 
The so1ubi1i七Yof a drug that is inso1ub1e in a par七icu1ar
so1vent can usually be increased significantly by七headdi七ion
of a coso1vent in which the drug is rnore so1ub1e. The vehic1e 
(solvent mix七ure)，having七heabi1i七Y 七oretain much drug， can 
be considered七oserve as a 1arge reservoir of七hedrug. 
工七 has been shown 七ha七 for a 1arge number of binary aqueous 
so1vent systems， the 10gari七hmof the so1ubi1i七Yof various drugs 
is direc七1ypropor七iona1七othe frac七ionof a cosolvent when七he
po1arity of七hedrug is significant1y 1ess than七ha七 ofei七her
49-51) 
solvent----'. The re1ation is expressed as fo11ows: 
log Cs' = 10g Cso +σf (Eq. 19) 
where Cs' and Cso = the so1ubi1i七iesof drug in the so1ven七
mixtures and that in pure water， respectively，σ= a constant 
which is related七othe solubilizing power of the cosolven七 for
七hedrug， and f =七hefraction of cosolvent. 
The drug re1ease through a partition membrane from systems 
consisted of coso1ven七s was considered. In七hecase where drug 
diffusion in the membrane is the rate-limiting step and a sink 
condi七ionis maintained in七herecep七orso1ution， as defined 
previous1y: 
Po = DoKo (Eq.20) 
when the donor solution is an aqueous solution， and 
p' D'K' (Eq. 21) 
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when七hedonor solu七ionis a mixed so1ven七， where PO， Do， and 
Ko are the permeabi1ity， diffusivity in the membrane， and dis由
tribution coefficient of七hedrug be七ween七hemembrane and donor 
so1ution， respec七ively， for七heaqueous so1u七ionsystem， and 
P'， D'， and K' are those for the cosolven七 sys七em，respective1y. 
Assuming that the diffusivity in七hemembrane is not affected 
by the composition of the donor solu七ion，Eq. 21 becomes: 
p' = DoK' (Eq. 22) 
Distribution coefficient can be expressed in terms of so1ubi1ity: 
(Eq. 23) 
and 
??? ???? (Eq. 24) 
where Cso， Cs'， and Csm are the so1ubi1ities of drug in water， 
a mixed solvent， and a membrane， respectively. From Eqs. 19-24， 
p' is given by: 
p' = po・10-σf (Eq. 25) 
Then， an equa七ionwhich may describe the release profile of drug 
through a partition membrane frorn systems consis七edof cosolvents 
is derived from Eq. 4 and Eq. 25: 
ーσ I:_~~AP ・10v"'CdA. o.._.. ^-σf exp (-AP.I0 v"'t/l V) (Eq. 26) 
or 
Mr =叶1-吋ザl戸山>} (Eq. 27) 
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where M~ = the amoun七 ofdrug originally introduced into the 
system. Similar1y， Eq. 28 can be derived from Eq. 17 and Eq. 25 
for hollow cylinders: 
、??、 ，
??
，
、?，??? ???，?? 、??????
?
???? ??
?
?????
???
??
????? ?
、?
?? ??? (Eq. 28) 
工nthe present inves七iga七ions，macrogol(po1yethylene glycol) 
400 was se1ected as a cosolven七， and the macrogol-water mixtures 
of various fractions were evalua七edas to七heirdrug release-
sustaining behavior. 
ー
17 
46) 5. Systems Consis七edof Oi1-in-Water Type Emu1sions 
An oi1-in-water七ypeemu1sion is a1so expected to serve as 
a reservoir for the drug wi七hconsiderable lipophilici七y. When 
an emulsion of tha七 sor七 whichcontains七hedrug mainly in its 
oil phase (because of high lip~d solubility of the drug) was 
app1ied to the drug release sys七em，sustained release of七he
drug may be achieved. The mechanism can be considered similarly 
七othat described in the mice11ar sys七em (Fig. 3， b and Fig. 4). 
Loss of drug in an aqueous phase in the donor medium due to per-
meation can be par七1ycompensated for by par七itionof the drug 
from an oil phase七0 七heaqueous phase. 
Emulsions are widely used in pharmaceutical prepara七ions• 
An emulsion， in its na七ure，is a thermodynamically uns七ab1esys七em，
i.e. fine droplets of oil are dispersed in a continuous aqueous 
phase. Therefore， coalescence or flocculation inevitably occurs 
among the dispersed phases due to the na七ural七endencyof. like 
molecules to coalesce. 
Various information for七hestability of emu1sions has been 
52，53) reported~-'~~I in which the effects of tempera七ure，oil fractions， 
concentrations of emuIsifiers， or many 0七herfactors on the emul-
sion stability are examined. The s七abilizationof七hesystem 
has been under challenging. If properties and/or phase composi-
tion of the components of the sys七emdo change during the use， 
the release behavior of the drug may be affec七edwhen emulsions 
are applied to the drug release system. 
EXPER工MENTAL
1. Hydro1ysis Studies 
The rates of hydrolysis of benzocaine and butamben in O.OSN 
NaOH so1utions were fo11owed in a constan七七emperaturece11 a七
30 0 • Initia1 concentra七ionsof each drug were 1/50 of their 
respective so1ubilities a七 30 0 • Ultravio1et (UV) spec七rawere 
repeatedly scanned at intervals of 10 min七ofo11ow their changes 
wi七htime due to hydrolytic breakdown emp10ying a double-beam 
recording spectrophotome七er. The percen七ageof the intact 
(unhydrolyzed) drug was calcu1ated from the absorbance of the 
reac七ionsolution using七heabsorptivity va1ues for benzocaine， 
butamben， and their hydroly七icproduct， p-aminobenzoic acid. 
2. Solubi1ity Studies 
An excess amount of butamben was placed into each via1 
containing a complexing agent， surfactant， or cosolvent at var-
ious concentrations. 、Thevials were immersed in a bath main-
tained at constant temperature (30.0 ~ 0.50 or 37.0土 0.50) and 
the contents were equilibrated by shaking or by stirring magnet-
ically for at least 24 hours. In the s-cyclodextrin systern， 
where a cornplex with lirnited solubili七ywas formed， or in the 
system which gave high bu七ambenso1ubi1ity， a 10nger equi1ibra-
tion period (2 to 3 days) was required. Equi1ibrated mixtures 
were then fi1tered quickly through a sintered-glass disk， and 
after appropriate dilution withdistil1ed water， samples were 
assayed for butamben contents. In the coso1vent systems， fil-
tered samples were diluted with ethano1 to avoid possible pre-
54) cipi七ationof bu七amben~~/. Analytical methods were as follows. 
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Spectropho七ometricAssay司ー 工ーn 七heabsence of any interfering 
ma七eria1，七heUV absorbance of butamben a七 287nm (入maxin 
aqueous 901u七ion) or at 295 nm (入 ine七hano1)was used七。max 
de七erminethe concen七ra七ionof bu七ambenin七hesamp1e. 
工nthe presence of 7四 (2-hydroxyethyl)theophy11ine，which 
shows its 入 at272 nm in the aqueous solution and interferes max 
with UV assay for butamben， the solubilities of butamben were 
measured by means of dual-wavelength UV spectrophotometry at the 
following two wavelengths，入 1 = 258 nm and入2 = 285 nm. 
GLC Assay ---Caffeine also interferes wi七hUV assay for bu七amben
because it shows its入 at272 nm in aqueous s01u七ions •max 
Concen七rationsof bu七ambenin solutions con七ainingcaffeine were 
de七erminedby GLC. A known amount of benzocaine (as interna1 
standard) was added七oa samp1e solution， and water was vacuum 
evaporated. The residue was subsequently dissolved in 50~1 of 
ch1oroform， and a 2-~1 portion of the chloroform so1ution was 
injected into the co1umn. 
GLC conditions were as follows: apparatus， gas chromato-
graph with a f1ame ionization detectori column， 2-m stainless 
stee1 with 1.5も OV-101on Shimali七eW (80 -100 mesh)i injection 
port temperature， 1730 ; detector temperature， 2750 ; nitrogen 
(carrier gas) flow rate， 30 m1/mini hydrogen flow rate， 25 m1/mini 
and air f10w rate， 940 ml/min. The re七en七iontimes for benzocaine 
(as interna1 standard)， butarnben， and caffeine were 1.9， 3.6， and 
4.3 min， respective1y. 
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3. Re1ease S七udiesIn Vitro 
3-1 Preparation of Test So1u七ionsof七heDrugs 
Drug Suspensェons---A known excess amoun七 ofdrug was added to 
disti11ed water with or wi七hou七 suspendingagent or surfac七ant
in flask， and the content was then vigorously agi七ated七oeffec七
better dispersion of drug particles for at least 10 hours a七
the七emperature.
Drug Solu七ions---A ca1culated amoun七 ofdrug was added to a 
solution containing each vehicle and disso1ved comple七e1y. 工n
order to obtain satura七eddrug so1utions，七hesame procedures 
as in so1ubi1ity studies were used excep七 forlarger volume of 
solutions. Equilibra七edmixtures were filtered just prior七o
permeation experiments. 
Emulsion~ ---An oil-in-water type emulsion was prepared in the 
following procedure. A weighed amount of butarnben was initial1y 
disso1ved in cotton seed oi1. Theoil solution was then poured 
in七othe aqueous sodium alginate solution containing a smal1 
amount of po1ysorbate 80 wi七hs七irring. An ultrasonic vibrator 
was used七oemulsify七heoi1 in water at 100 watts for 30 sec. 
The emu1sion七husformu1ated was found七obe of an oil-in-water 
type as de七errninedby七hedilution method and七hedye-solubili七Y
test. 
3-2 Evalua七ionof Emulsion Stability 
To examine the physical stabili七yof the ernulsions， emulsions 
were prepared using various concen七ra七ions (0.5 -2.0毛) of sodium 
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a1ginate and various oi1 frac七ions (10 -50毛). Emu1sions七hus
prepared were kept s七andingin test七ubes (10-mm diameter) for 
up to 5 days a七 roomtempera七ure. The emu1sions which resulted 
in phase separa七ioninto a superna七an七 clearphase and a lower 
七urbidphase were regarded as uns七ab1e.
3-3 Permea七ionExperiments Using Diffusion Ce11s 
Three types of diffusion cells were used in七hiswork. 
permeation Experiments Using Diffusion Cell Type 1 --- The quasi-
s七eady-statediffusion ce11 described by M・Nakanoand N.K・pate132)
was used and is shown schematica11y in Fig. 5 (Type 1). 
Membrane 
-・圃・・・圃・・圃.
-・・b ・
・ー・ ・園田
Donor solution Recep七orsolution 
Flgure 5. I11us七rationof the diffusion ce11 type 1 
used in the permeation experiments. 
The ce11 is consisted of two half cells made of stainless stee1， 
a poly七etrafluoroe七hyleneO-ring， and a membrane. A silicone 
membrane and the O-ring were p1aced between the ce11 ha1ves， and 
the halves were joined tightly by nu七-and-bolts. The diameter 
of the membrane area avi1able for diffusion was 32 mm. 
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The cell was initially equilibra七edovernight in a shaker 
bath maintained at 30.0 ! 0.50 with 50 ml of dis七illedwater in 
bo七harms. Wa七erwas removed by suc七ion; 40 ml of O.lN HCl 
solution (to maintain a sink condition wi七hrespec七七o七heperme-
able species in the receptor solu七ionby pro七onatingthe permeated 
drug) was added to one arm， and an equal volume of a test solu七ion
was pipet七edin七oano七herarm. All七hesolutions were warrned七。
300 before being placed in七o 七hecell. 
The cell was mechanically shaken horizontal1y at a rate of 
70 t 2 strokes/min. Only in七hesuspensionsys七emin water， 
ins七eadof shaking the cell itself，七heconten七sof both arms of 
the cell were stirred with propellers attached to electric motors 
七oeffect better dispersion of七hesolid drug. A 0.5 ml portion 
of the receptor solution was pipetted out at prede七erminedtime 
in七ervalsand diluted with pH 6 phosphate buffer. Subsequent1y 
UV absorbance of the unprotonated drug was measured at 287 nm. 
Permeation Experiments Using Diffusion Cell Type 2 ---The newly 
30) designed diffusion apparatus is illustrated in Fig. 6 (Type 2r 
The g1ass cel1 consisted of the donor and receptor compartments 
(22 mm in inner diameter and 40 mm long in one compartment)， 
and the membrane (availab1e area = 4.52 cm2) placed between七hem.
The cell was immersed in a jacketed container maintained at 
30.0士 0.10 by circula七inqwa七erfrom the constant temperature 
bath. The content of each compar七mentwas stirred with a magne七ic
spin-fin (20 mm in diameter and 15 mm in thickness， Toyo Scientific 
products Co.， Osaka) which was rotated by a magnet attached to 
an electric motor. 
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Flgure 6. 工11us七rationof the diffusion ce11 type 2 used in 
the permeation experimen七s.
1. jacketed con七aineri 2， glass ce11i 3， donor solutioni 
4， receptor so1utioni 5， membranei 6， magnetic spin-fin; 7， cap; 
8， ce11 c1amp; 9， bathing wa七er; 10， rnagne七i 11， in1et water; 
12， out1et water. 
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S七irringcondition is repor七ed七ocon七ributemuch七0 七he
55) re1ease ra七eof drug in relation to diffusion 1ayer effect 
A preliminary experimen七 showed七hata ro七a七ingspeed of less 
than 200 rpm resulted in significan七lyslow re1ease of七hedrug， 
and that increasing the speed more than 400 rpm did no七 giveany 
noticeab1e increase in re1ease rate. 工n 七hisexperimen七，七he
ro七atingspeed was kep七 ataround 500 rpm. Ten mi11i1i七ersof 
solu七ionoccupied each compar七ment. A hydrochloric acid solution 
at pH 1.0 was placed in the recep七orcompartmen七. At scheduled 
times， an aliquot of the receptor solution was pipe七七edou七 for 
UV deter.mination and the same volume of the hydrochloric acid 
solution was added to the receptor compartment to replace七he
reduced volume. After di1ution of the sample with pH 6 phospha七e
buffer， UV absorbance of the unprotonated drug was measured at 
287 nm. 
Permeation Experiments Using Diffusion Cel1 Type 3 ---Diffusion 
cell type 3 is illustrated schematical1y in Fig. 7. The compo-
sition of this cell is essentially the same as that of type 2. 
The volumes of donor and receptor compartments were 45 ml and 
72 m1， respective1y. The membrane area avai1ab1e for diffusion 
was 12.6 cm2 • The rotating speed of spin-fin (35 mm in diameter 
and 12 mm in thickness) was kept at around 400 rpm. At schedu1ed 
times， 25 m1 of七hereceptor solution was pipet七edout for UV 
determination and the same volume of the hydroch1oric acid so1u-
tion was added. UV absorbance of七heprotonated drug was read 
at入 ofeach drug in acidic so1utions at pH 1.0: 227 nm for max 
butamben， n-penty1 p-aminobenzoate， and procaine~ 229 nm for 
tetracaine; and 263 nm for lidocaine. 
J L 1'-
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Flgure 7. 工llustrationof the diffusion cel1 type 3 used in 
the permeation experiments. 
Each part corresponds to that of the cel1七ype2. 
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3-4 Permeation Experimen七sUsing Capsules 
preparation of Silicone Capsules ---Two七ypesof capsules were 
prepared from Silastic rnedica1 grade tubings. Capsu1e type 1， 
prepared from tubing 6.4 mm inner diame七erand 9.5 mm outer 
diameter， had an inner volume of 1 mlj whereas capsule type 2， 
prepared from tubing' 3.35 mm i.d. and 4.65 mm o.d.， had an inner 
volume of 0.2 ml. The七ubeswere cu七 in七ocy1inders of the 
appropriate leng七h. 工ncapsu1e type 1， bo七hends were closed 
by polymethyl methacrylate pla七es (3-mm七hick，one of which had 
a hole in the center) cemented in place with Silastic Medical 
Adhesive Type A. Af七erallowing the adhesive to harden for 20 
hours， 1 ml of. a test solution was introduced into the capsule 
wi七ha syringe through the ho1e. The opening was then sea1ed 
with the adhesive. 工ncapsule type 2， both ends were c10sed by 
glass beads (3.5-mm diameter) with the adhesive. 
permeation Experiments ---The release rate of bu七ambenfrom the 
capsules in vitro was measured a七 37.0 土 0.5 0 • Capsules were 
suspended with a cotton thread in erlenmeyer flasks or tes七
tubes containing hydrochloric acid so1utions at pH 1.0. The 
flasks or tubes were immersed in a constant temperature ba七h.
At given intervals， capsules were taken out， quickly rinsed 
with dis七illedwater， wiped free of water to prevent possible 
carry-over， and transferred to vessels containing fresh hydro-
chloric acid solutions a七 37 0 • A fresh hydrochloric acid 
solution was employed as the desorbing medium at each sampling 
time in order to maintain a sink condi七ion. UV absorbance of 
七hedesorbing solu七ionwas read at 227 nm， the入maxof protonated 
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butamben in the hydroch10ric acid s01u七ion. The amoun七 of七he
drug re1ease was ca1cu1a七edfrom七heabsorbance data. Mos七 of
七here1ease rate experiments in vi七rowere carried ou七 in七rip1icate.
4. Release S七udies工nVivo 
The same silicone capsules as those used in七hestudies 
in vitro (capsule七ype1) were imp1anted subcu七aneous1yin七he
dorsa1 side of rabbits anes七hetizedby means of a sodium pen七O四
barbital injection. The amoun七 ofdrug re1eased from七hecapsules 
was measured every 0七herday up to 10 days. A七 schedu1edtime， 
七hecapsu1e was removed from七heimp1anted site and rinsed with 
dis七i11edwater. After cu七tingthe capsule open with a b1ade， 
0.5 ml of七hecon七en七swas pipetted out and di1u七edappropriate1y 
wi七hdisti11ed wa七er. UV absorbance of the di1u七edsamp1e was 
read at 287 nm，七he入 ofunionized butamben in water. The max 
amount of drug released was ca1culated by subtracting the amount 
remaining in the capsule from that introduced ini七ially. No 
substance which might penetra七einto七hecapsule and interfere 
wi七hthe UV assay was detected. The release studies in vivo 
were carried out in triplica七e.
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5. Source of Materia1s Used 
Butarnben (n-buty1 p-aminobenzoate)， benzocaine (e七hyl
p-aminobenzoa七e)，p-nitrobenzoy1 ch1oride， n-penty1 alcohol， and 
7-(2-hydroxyethyl)theophy11ine， al1 of reagen七 grade，dodecy1-
七rimethy1ammoniumch1oride， and sodium alginate were purchased 
from Tokyo Kasei Kogyo Co.， Tokyoi methyl ce11u1ose-500 cps and 
4000 cps， caffeine monohydrate， reagen七 grade，po1ysorba七e80， 
sodium dodecy1 sulfate， 1aury1pyridinium chloride， macrogol (po1y-
ethylene glycol) 400 and 20000， from Wako Pure Chemica1 Industries， 
Osakai po1yoxye七hy1enelauryl ether (BL-9EX)， from Nikko Chemicals， 
Tokyoi povidone K-15 (average MW ~ 10000)， from Daiichi Pure 
Chemicals， Tokyoiα 由 cyclodex七rin，from Teijin Co.， Tokyoi cotton 
seed oi1， from Hayashi Ichiji Shohten， Tokyoi procaine hydro-
ch1oride， JP grade， from Iwaki Pharmaceu七ica1s，Tokyoi 七e七racaine
hydroch1oride， from Kyorin Pharmaceutica1s， Tokyoi and 1idocaine， 
from Fujisawa Pharmaceu七icalIndustries， Osaka. 
n-Pen七ylp-aminobenzoa七ewas synthe七izedfo11owing the 
56) procedures described by E. Epstein et a1.-v， s七artingfrom p-nitro-
benzoy1 ch10ride and n-pentyl alcohol. The fina1 product was 
identified as n-pentyl p-aminobenzoate by七hefo11owing analytical 
da七a:
Ana1 • Calcd for C12H17N02: C， 69.54; H， 8.27; N， 6.76; 
Found: C， 69.54; H， 8.51i N， 6.82. 
uv入:zm(ε): 285 (口500)， UV入日Cl(pHl・0) nm(ε): 227(12850)・
max 
Silicone membranes (Silastic medical grade silicone rubber 
sheeting， nonreinforced) in 1abeled thicknesses of 0.005 and 0.01 
inches， silicone七ubings (Silastic medical grade tubing) 6.4 mm 
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inner diameter and 9.5 mm outer diarne七erand 3.35 mm i.d. and 
4.65 mm o.d.， and Silastic Medical Adhesive Type A were purchased 
from Dow Corning， Midland， Michigan. Ethylene-vinyl ace七ate
membrane (EVAFLEX， vinyl acetate con七entof 17も， labeled thick-
ness of 0.018 mm) was obtained from Mitsui Polychemicals Co.， 
Tokyo. 
All chemicals were used as received. Silicone rnembranes 
and tubings were washed with disti11ed wa七erand ethanol before 
use. 
6. 工nstrumentations
A double-beam/difference/dual-wavelength recording spectro-
photometer (Model UV-300， Shimadzu Manufacturing Co.， Tokyo) was 
used in the hydrolysis studies. A dual-waveleng七h・spec七rophoto-
meter (Model 556， Hitachi Manufacturing Co.， Tokyo) was used in 
the solubility study in the presence of UV-absorbing interfering 
substances. In other spectrophotome七ricalassays， Hitachi double-
beam spectrophotome七er，Model 200-20， was used. 
A gas-liquid chromatograph (Shimadzu Model GC-4APF) was used 
in the solubility study. 
T An incubator (Model M-IOO.， Taiyo Kagaku Kogyo Co.， Tokyo) 
was used as a constant七emperatureshaking bath. A cons七an七
temperature bath (Model FS， Haake， Berlin) and DC mo七orsequipped 
with rotating-speed meters (Model DC-6R， Tokyo Rikakikai， Tokyo) 
were employed in the permeation experiments using diffusion cells 
type 2 and 3. 
工nprepara七ionof emulsions， an ultrasonic vibrator (Model 
UR-200P， Tomy Seiko Co.， Tokyo) was used. 
PART工: STUDIES ON THE SELECT工ONOF A SU工TABLEDRUG 
1. Some Physicochemica1 Properties of Several Local Anesthe七ics
57) and Their Permeabi1ities to七heSi1icone Membrane 
工nTab1e 1 are listed七he10cal anes七heticsexamined a10ng 
with pKa values and permeabili七ies七o silicone membrane. 
Genera11y， usefu1 1oca1 anes七he七icscon七aina lipophilic (rnostly 
arorna七ic) por七ion，an intermedia七echain， and a hydrophilic (of七en
??????????? ???????????↑ 』?? ??????、???????????? ???? ????↑ 』????
Such s七ruc七uralcharacteris七icscan be seen in those drugs listed 
here (procaine， tetracaine， and lidocaine). Most local anesthetics 
have their pKa's between 8 and 9 on七hetertiary amino group， 
below which positive1y charged (less lipophi1ic) rno1ecu1es are 
dominant in solutions. 
On the other hand， benzocaine， butamben， and n-pentyl p-
aminobenzoate， because of the absence of 七er七laryamlno group， 
have very 10w pKa values above which uncharged forms are dominant 
in solutions. 
In the last co1umn， permeabi1ity of each loca1 anesthetic 
to the si1icone membrane is shown. The order in rnagnitude of P 
(procaineぐ1idocaineぐ七e七racaine) is in good agreernent with七hat
58-60) 
of lipophi1icity as well as七helocal anes七heticpo七ency
Cornpared to those drugs， benzocaine， butarnben， and the n-pentyl 
ester showed rather high permeabilities so七ha七七hesedrugs are 
also expected to be po七ent. 工nfact， benzocaine is reported to 
61) be a potent local anesthetic 
工norder to release a drug having pKa above through such 
a rnernbrane as silicone， pH of a drug solution must be above 9 
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to keep七hedrug in an uncharged (permeable) form. 
Alkalinization of the medium， on七he0七herhand， may cause 
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and the n-pentyl ester have low pKa values，七heirreleases from 
solu七ionsof neutral pH range through a silicone membrane is 
a七七ainable. From a standpoin七 of chemical stabili七y，the use of 
a neutral pH condition is preferable. 
For the series of n-alkyl p-arninobenzoa七es，the permeability 
to a silicone memQrane， which is closely related to lipophilicity， 
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in the present S七udy (Tab1e 1). 
In Fig. 8 are shown the release profiles of benzocaine and 
butamben through a silicone membrane from aqueous suspensions 
using diffusion cel1 type 1. Bo七hdrugs were released at nearly 
七hesame rate. The release rate of drug from i七ssuspension is 
a function of permeability and solubility as we11 as a membrane 
thickness (Eq. 7). As a resul七， parabolical relationship between 
the flux and side-chain length exists. The maximum s七eady-sta七e
flux through a silicone membrane was reported to be obtained when 
55) 
a saturated 501u七ionof n-propyl or n-butyl ester was applied 
Similar release experimen七swere carried out by using diffu-
sion cell type 2 and the result is shown in Fig. 9. Butarnben was 
released a七 ahigher rate七hanbenzocaine. This result is in 
agreernent wi七hthe reported one. Aqueous solubilities of 
benzocaine， butamben， and the n-pentyl ester were determined 
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0.27 and 1.2， 7.5， be 七o30 。a七
be can 1) Tab1e l.n (1isted permeabi1ity and so1ubi1ity of 
mo1es/cm/sec 10 -1 1 〉ぐ0.513 10-11， X 1.44 l o-11， )( 0.975 ca1cu1ated: 
respectively. ester， n-pentyl 七heand butamben， benzocaine， for 
七oproved bu七ambendrugs， three the among resul七s，七heseFrom 
sa七ura七eda from membrane silicone a 七hroughf1ux highes七七he????
even 8， Fig. l.n butamben of ra七erelease reduced The solution. 
motor-by stirred were compartments both l.n contents 七he七hough
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Flgure 10. 
bu tamben (0) 
37 
七ionsof unhydrolyzed benzocaine and butarnben vs. 七imeqave 
linear profiles (pseudo-first-order reac七ion). The ra七econs七an七
k and七hehalf-life for the reac七ionwere determined from七he
slope and are lis七edin Table 工工. Benzocaine was found to be 
hydrolyzed more rapidly than bu七arnben， indicating七ha七 butarnben
is more s七ab1eagainst hydrolysis in alkaline s01u七ionsthan 
benzocaine. A similar observa七ionhas been repor七edrecently 
66) by Smi七h，et a1. 
In suspensions， the concen七rationof the drug in s01u七ion
is kept constant a七 i七ss01ubi1ity， Cs. The ra七eof hydr01ysis 
-dC/dt can then be wri七tenby: 
? ? ?
kCs 
where k = firs七-orderra七econstant. Since both k and Cs are 
cons七anta七 constant七emperatureand pH，七herate of hydrolysis 
becomes constant (zero-order reaction). Firs七-orderrate con-
stan七s，solubilities， and rates in suspensions for benzocaine 
and butamben are listed in Table 工工. 工tcan be interpreted 
that butamben in suspension is more s七ab1eagainst a1kaline 
hydrolysis than benzocaine in suspension by about 10 folds due 
to its lower solubi1ity and smal1er rate cons七antagainst hydro-
1ysis. 
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3. Summary 
Six local anesthe七iCSi procaine， tetracaine， lidocaine， 
benzocaine， butamben， and n-pen七ylp-aminobenzoa七ewere evalu-
a七edfor their possible use in a silicone membrane-con七rolled
release system. For procaine， te七racaine，and lidocaine， alka-
line conditions were needed to ob七ainan observable amoun七 of
release. Such conditions are no七 preferablefrom a s七andpoin七
of chemical s七ability. Benzocaine， butamben， and七hen-pen七yl
ester， on the other hand， do no七 necessi七a七ealkaline conditions 
due to their low pKa values. 工naddi七ion，these n-alkyl p-amino-
benzoa七eesters exhibi七 relativelyhigh permeabili七iesto a 
silicone membrane. Among七hehomologs， butamben showed the 
highest release rate from its satura七edsolution. 
Benzocaine and bu七ambenwere compared for their stabilities 
against hydrolytic degradations in O.05N NaOH so1u七ions. Ca1-
cula七edstability of bu七ambenin suspensions was about 10七imes
greater than benzocaine due to a smaller hydrolytic rate con-
s七antand smaller solubility. 
From七hoses七udieson permeability and s七ability，it may 
be suggested that butamben is preferable七othe other 10cal 
anesthetics exarnined herein when used in七hedelivery system 
employing a par七itionrnembrane as a release-controlling barrier. 
It can be general1y sta七ed七hatin such a delivery sys七ern，exam-
inations of a drug for its permeabili七Y 七othe mernbrane and 
stability in the reservoir give a meaningful suggestion to a 
proper choice of a drug from a series of hornologs. 
PART 工工: RELEASE OF BUTAMBEN FROM SYSTEMS CONTA工NING
SOLUBLE COMPLEXES 
24，30) 1. So1ubi1ization of Butamben by Comp1ex Formation 
工nFig. 11，七heso1ubi1i七iesof butamben in solutions of 
five comp1exing agents are presented. The so1ubi1ity of the 
drug increased 1inear1y wi七hthe concen七rationof povidone， 
7-(2-hydroxye七hy1)theophy11ine (HET)， caffeine， and αーcyc10dex七rin.
The linearity was observed on1y in七heconcen七rationrange up七。
1.1も fors-cyc1odextrin， indica七ingtha七 s-cyc1odextrinformed 
a complex with a 1imited solubility (the solubility of the complex 
was ca1cu1ated to be 7 mM a七 300) • 
With the assumption tha七七hesecomp1exes are of七he1:1七ype，
stabi1ity cons七antsof butamben comp1exes were ca1cu1ated by七he
Higuchi and Connors equation31)七obe 5.4 )( 102M-1， 2.2 X 103 M-1， 
61 M-1， 32 M-1， and 2.9 M-1 for αーcyc10dex七rin， s-cyc1odex七rin，
HET， and povidone (where the mo1ecu1ar weight of the repeating 
unit， viny1pyrro1idone， was used in the ca1cu1ation)， respec七ive1y.
Thus， cyc10dex七rins， especially s-cyc1odextrin， were found to 
form stab1e comp1exes with butamben. Then follows caffeine， and 
HET， which is 1ess hydrophobic than caffeine， interacted rather 
weak1y with butamben. The interac七ionbe七weenpovidone and 
bu七ambenwas very smal1. 
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2. Release Profiles of Bu七ambenfrom Sys七ernsContaining 
24，30) Soluble Complexes-.' 
Permeation profiles of the drug from suspension sys七ems，
which may give a maximurn re1ease rate， can be a good reference 
七oevaluate each system containing a cornplexing agen七. Before 
七heeffects of comp1exation on permeation are considered， perme-
ation of bu七ambenfrorn suspensions were examined. 
工nFig. 12 are shown七heperrneation behaviors of bu七amben
frorn the suspensions in water， 0.1も and0.25も me七hy1ce11ulose
solu七ions. A1though七heso1ubi1i七iesof bu七ambenwere the same 
in七hethree cases， the permeation profi1es varied significant1y. 
When the concentration of methylcel1u1ose was increased frorn 0.1亀
to 0.25も， the release rate slowed down and a constant (zero-order) 
release was no longer ob七ainedin spi七eof increased drug-suspend-
ing action. The release ra七eof butamben was greater from the 
propel1er-s七irredsuspension in wa七erthan from the七wornethyl-
ce11ulose suspensions， indicating七hatthe bet七erdispersion and 
reduced diffusion layer七hicknessaround the solid in the former 
favor the dissolu七ionof the drug which， in turn， favors the 
transport of the drug. 工tcan then be stated that the re1ease 
rate of butamben in the methylce11ulose suspension systerns is 
not membrane-limi七ed. Such an incidence might occur for七he
drug with considerab1y slow disso1ution rate. 
Permea七ionprofiles of butamben from i七ssa七uratedsolutions 
in solu七ionsof various complexing agen七s，and frorn七heplain 
saturated solu七ion (no solid nor complexing agen七) are shown in 
Fig. 13. When the plain saturated solu七ionwas used as a donor 
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solu七ion，七herate of release decreased rapidly as concen七ration
in the donor solution decreased. Only abou七 20毛 ofthe drug 
rernained in the donor solution after 8 hr. When sa七urated
so1utions of七hedrug containing cornp1exing agen七swere used， 
the re1ease curve fell be七weenthe line represen七inq七heperrnea-
七ionfrom the suspension and七hecurve for七heplain solu七ion， 
indica七ingtha七 complexa七ionhas effec七son the perrneation pa七tern
of七hedrug・
Before further considera七ions，it is necessary七odiscuss 
七hepossibility of permea七ionof species 0七herthan the free 
(uncomp1exed) drug， such as the comp1exing agen七sor the comp1exes， 
a1though七hispossibility was assumed no七七obe七hecase in the 
sec七ionof THEORET工CALCONS工DERAT工ONS. Among the complexing agen七s
employed in this section，αand s-cyclodextrins and povidone are 
assumed not七opermeate七hrough七hemembrane七oa de七ectab1eextent 
due七o their negligib1e 1ipophilici七y. Caffeine and 7-(2-hydroxy-
ethyl)七heophylline (HET) ， on七heother hand， do permeate七hrough
七hemembrane. However， much sma11er permeabilities of caffeine 
-9 __ 2 ~ _ _ _ ¥ 32) (P = 8 x 10-~crn~/sec)JWI and HET* in comparison with七ha七 of
butamben (P = 1.2 X 10-Scm2/sec) warran七 theassumption七ha七七he
concentra七ionof caffeine or HET in the donor solution remains 
essentially constan七七hro1.lghou七 theperrneation s七udy.
As for the permeation of the comp1exed species， the cyc1o-
dextrins and povidone complexes may be considered impermeable 
*Preliminary experimen七sshowed tha七 less 七han0.1毛 ofthe total 
drug permeated in 7 days. 
silicone the 1n七oparti七エonno七
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do agents complexing 七heses1nce 
a a七permea七edhad complexes HET and caffeine 七he工fmembrane. 
七hesefrom bu七ambenof ra七erelease ini七ial七herate， significant 
drug 七hefrom 七hose七hangreater much been have would systerns 
七hese1n present 1S drug much as times several S1nce SUspens1.on， 
was however， This， solution. saturated plain the 1n as systems 
complex caffeine-butamben the of permeability The case. the not 
smal1er much be to expected 15 any， if complex， HET-butamben or 
the 1n ? ??
?? ????? ?permeable the Thu5， butamben. free of that than 
free the essential1y be to aS5umed lS examined here systems 
alone. drug (uncomplexed) 
informa七ionprovides studies) solubi1i七Ythe (in 11 Fig・
present complexed drug and free the of amount exact 七heconcern1.ng 
and HET， (caffeine， sys七emsthree the of so1ution donor the l.n 
drug free 七heof amoun七the 七l.me，zer。At 七1me.zero at povidone) 
each by solubilized drug The systems. all 1.n same 七hewas 
values ?????corresponding 七heby ?????1.5 agen七comp1exing 
wa七er.plain 1.n drug the of solubility the ml.nus 
solubilized drug 七heof amoun七七hesystem， povidone 七heIn 
the 1.n permea七eddrug 七heof amoun七cumulative The smal1. was 
sa七uratedpl.ain the from 七ha七七hanlarger al七houghperiod， 8-hr 
sys七ems.two 。七her七he1.n than sma11er much was solu七ion， 
solubi1ities 七hesystems， s-cyc1odextrin 1毛and caffeine 2毛In 
the Therefore， 11) . Fig・1n rnM， (7.7 same the were bu七ambenof 
were permeation for comp1exed) and (free drug of amounts 七otal
Consequen七ly，cons七ant.s七abilitydifferen七with even same the 
infinite 七ocon七inuedwere 13) (Fig. studies ???↑ 」??????the if 
? ? ? ?
?? ? ?
47 
七ime，七hepermeation profiles for七hesetwo sys七emswould have 
converged七oa common plateau. 
Under七hesecircums七ances， since s-cyclodex七rinforms a 
complex wi七ha grea七erstabili七ycons七ant，七heconcentration of 
the free drug (permeable species) in the s-cyclodex七rinsystem 
during the initial s七ageof perrneation tends to be smaller than 
七ha七 inthe caffeine system and， consequently， the release-ra七e
is ini七iallysmaller. The perrneation profiles presen七edin 
Fig. 13 for the firs七 8-hrperiod clearly indicate七hatthe rate 
of release was ini七ial1ysmaller from the s-cyc1odex七rinsystem 
七hanfrom七hecaffeine sys七em. Since both sys七emsshould have 
a common plateau， the faster initial rate of re1ease in七he
2% caffeine sys七emleads to a rapid decline in the ra七eand 
to a shorter release time七hanin the 1も s-cyc1odextrinsystem. 
The permeation profile from a 1毛 caffeinesys七emis a1so 
shown in Fig. 14. Since the amount of to七aldrug in 1も s-cyclo-
dextrin was grea七erthan that in the 1も caffeinesystem (Fig. 11)， 
more drug was expec七edto be released from七he1も s-cyclodextrin
system七hanfrom the 1毛 caffeinesystem a七 infinitetime， even 
though the release rates were identical during七hefirst 5 hr. 
It was sugges七edfrom these resul七s七hat七herate and七hedura-
tion of drug release were a function of七hes七abilitycons七an七
of cornplex as wel1 as the七otalamount of drug added. 
工norder to confirrn this proposition， further 1ong-term 
permea七ionstudies were carried out for 1.6も α-cyclodextrin，
1も s-cyclodextrin，and 4も HETsystems using the diffusion cel1 
type 2 (see EXPERlMENTAL section). Solubilities of butarnben in 
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七hethree sys七emswere a11 abou七 7.7mM (Fig. 11). Therefore， 
七heto七alamounts of the drug origina11y con七ainedin七hedonor 
solutions were a1most七hesame in the七hreecases， so七ha七 their
permea七ionprofi1es shou1d have a common pla七eaua七 infini七e
七1me.
The resu1ts are shown in Fig. 15. When a plain saturated 
solution was used， 95も ofthe七ota1drug original1y contained 
in the donor solution was re1eased in 8 hours (Fig. 15，工nset). 
For the HET sys七em，the drug was released almost completely within 
60 hours. For the α-and B-cyclodextrin systems， on the 0七her
hand，七herelease continued even after 120 hours. 
The fol1owing conclusions may therefore be drawn for七he
release of drug from i七ssa七ura七edsolu七ioncontaining various 
amounts of complexing agents. If such systems are capable of 
forming soluble， membrane-impermeable complexes， the release ra七e
of drug from such systems is greater than tha七 from七heplain 
saturated solution of the drug， although never exceeding that 
from the suspension in water. Control of the release profile 
of drug between these limits may be possible by means of a proper 
choice of complexing agents. It is evident tha七 themore s七able
the complex is， the grea七eris七hereservoir of the drug avail-
able for release. 
工七 has also been shown that for such systems as the present 
ones (i.e. when the saturated solution containing the same amoun七
of drug is used)， the more stable the complex is， the slower is 
the initial rate of release but the longer is the time required 
for complete release. 
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3. Summary 
The effects of caffeine， 7ー(2-hydroxyethyl)七heophylline，
α-and s-cyclodex七rins，and povidone on the permea七ionbehavior 
of butamben from saturated solutions con七ainingthese complexing 
agen七sthrough a silicone membrane were inves七iqa七edat 30 0 • 
Release-sus七ainingbehavior was evaluated for the five sys七ems.
工nall sys七ems，七heseagents increased the ra七eof bu七amben
release over七heplain saturated solution. The rank order of 
the sustaining power was in agreemen七 with七heorder of stabili七Y
of each complex: 七heeffec七 wasmore pronounced wi七han agen七
which forms a more s七ablecomplex with the drug. 
From the results presen七edin七hispart， the following 
generaliza七ioncan be made. For a fixed total (free and complexed) 
amoun七 ofdrug available for release， sustained release is 
associated with systems con七ainingmore stable complexes. 
A desired release profile of drug can also be achieved by a proper 
choice of a complexing agen七. Therefore， control of permeation 
of drug by means of complexa七ionmay find its prac七icalvalue 
in obtaining slow sus七ainedrelease from membrane-encapsula七ed
dosage forms containing drugs in solu七ion• 
. 
PART 工工工: RELEASE OF BUTAMBEN FROM SYSTEMS CONTA工N工NGM工CELLES
30) 1. Mice11ar So1ubi1ization of Bu七amben
So1ubi1i七ydiagrams of bu七ambenin七hepresence of three 
types of surfac七ants: anionic， cationic， and nonionic 5urfactan七5，
are shown in Fig. 16. The so1ubi1ity of七hedrug increased 
1inearly with the concen七ra七ionof七hesurfactants above七heir
cri七icalmice11e concen七rations (cmc). Among七he七hreesurfac-
tants used， dodecy1trimethylammonium chloride， a ca七ionicsur-
factan七， had a relative1y high cmc (abou七 0.4毛) and solubilized 
butamben七oa significant ex七entat higher concen七ra七ion5. The 
so1ubility of butamben in 2毛 solu七ionof the surfactant was about 
80 times七ha七 inwater. Sodium dodecyl sulfate (anionic) and 
polysorba七e80 (nonionic) so1ubilized bu七ambensimilarly but七。
a sma11er extent than dodecyltrime七hylammoniumchloride. Reported 
cmc values at 250 for七hesurfac七an七s，a1though various values 
67-71) have been reported， are: around 0.2も forsodium dodecyl 
72-75) sulfatei around 0.4毛 fordodecyltrimethylammonium ioni and 
76，77) around 0.006も forpo1ysorbate 80. Similar values can be 
es七i11a七edfrom the diagrams shown in Fig. 16. 
工ncontrast七obu七amben，benzocaine was solubilized to a 
smal1er extent (Fig. 17). The solubility of butamben in 2毛
dodecyltrimethylammonium chloride so1u七ion (Fig. 16) was nearly 
twice tha七 ofbenzocaine. Greater hydrophobicity of butamben 
or its higher affinity七o the micelle might be a reason for a 
greater solubility of butamben七hanbenzocaine. Thus， much 
greater amount can be retained in the surfactant solution by 
using butamben. 
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2. Release Profiles of Butamben from Systems Containing Micelles 
工nFig. 18 are shown shor七-termrelease profi1es of bu七amben
from i七ssa七uratedsolu七ionsin 2も solu七ionsof七hreesurfac七an七s:
dodecyltrimethy1ammonium chloride， sodium dodecyl sulfate， and 
polysorbate 80. Up to 8 hours， a nearly cons七antrelease ra七e
was ob七ainedin七hethree cases (when the linear-regression 
analysis was applied七o 七he七hreeprofiles， correla七ioncoeffi-
cients of grea七er七han0.9998 were obtained). Dodecyltrime七hyl-
ammonium chloride exhibi七edexcellen七 ability七omaintain constant 
release of七hedrug which was very close七0 七ha七 fromthe suspen-
sion. Polysorba七e80 and sodiurn dodecy1 sulfa七esustained七he
release to a somewhat smaller exten七 thandodecyltrirnethylammonium 
chloride. The superior release-sustaining power of dodecyl七ri-
me七hylammoniumchloride corresponds七oi七sgrea七ersolubilizing 
abili七yshown in Fig. 16. Therefore， a surfactant which， above 
its cmc， can solubilize七hedrug to a greater ex七en七 seemsto 
have a 1arger re1ease-sustaining power. Thus， mice11es were 
proved to serve as reservoirs which can compensate for 10ss of 
the drug from the donor solution by parti七ionof the drug from 
micel1es into the bu1k solu七ion. 
工nFig. 19 is il1us七rateda long-term release profile of 
butamben from its sa七ura七edsolu七ionin 2も solutionof dodecyl-
trirnethylammoniurn chloride. For comparison， the release profile 
frorn a butamben suspension， which was extrapolated from the shor七-
term s七udyup七o8 hours， is also shown. 工n the systems contain-
ing soluble cornplexes which were described in PART 工工， a rapid 
decrease in release rate was observed after 1 day. 工nthe system 
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shown in Fig. 19， on七heother hand， a decrease in release ra七e
was very gradua1 a1七houghthe re1ease profi1e was somewhat below 
七ha七 frorn七hesuspension. This surfac七an七 hasproved to possess 
greater sus七ainingpower in re1ease of the drug due七oi七s
abi1ity七ore七ainmuch drug in micelles which serves as a 
reserv01r. 
3. Comparison be七ween Theory and Experimen七a1Resul七s45，46)
工nthe f0110wing experiments，七heapp1icability of Eq. 15 
(or its rewri七七enform， Eq. 16) 七odescribe the permeation 
profi1e of drugs from the sys七emscon七ainingmice11es has been 
tested. 
The fo110wing terms which appear in Eq. 16 were determined 
direct1y: A = 4.52 cm2， 1 = 2.48 X 10-2 cm for silicone membrane 
(measured thickness whereas七he1abe1ed thickness was 0.01 inch 
= 2.54 X 10-2 cm) and 1.8 x 10-3 cm for ethy1ene-viny1 acetate 
copo1ymer membrane (1abeled thickness)， V = 10 m1， Cs = 1.2メ 10-6
m01es/cm3 (deterrnined a七 300). Cs was deterrnined by so1ubili七Y
measuremen七sin each case. When a drug suspension is p1aced in 
七hedonor compar七ment，a constant re1ease rate is obtained so 
七ha七 theP value can be ca1cu1ated from Eq. 7. 
工thas been realized tha七 thepresence of diffusion 1ayer 
should be七akeninto account when drug permeation through mem-
55) brane is considered--I .工nfact， diffusion layer-effec七 have
been reported for perrnea七ionof pheny1butazone七hrougha silicone 
78) membrane，uJ. In particu1ar， the contribution of diffusion layer 
becomes apparent when the membrane is thin and the agita七ion
59 
78) 
of solutions is mild'-'. 工nthe present investiga七ion，七he
diffusion cell type 2 was used and the solu七ionson bo七hsides 
of the membrane were vigorously agitated (see EXPER工MENTALsec-
七ion). Therefore，七heassump七ionthat contribution of the diffu-
sion layer-effect at the membrane surface can be neglec七edmay 
no七 causea significant error when analyzing七heda七a.
Fig. 20 shows release profiles of butamben from suspensions 
in wa七eras well as surfac七antso1utions. 工nboth cases， 1inear 
profiles are ob七ainedduring七heexperirnental period. A slight 
increase in the release rate was observed in the permeation from 
七hesuspension containing a surfactant. 工naddition， an increase 
in the concentra七ionof surfac七antsin七hesuspension showed a 
七endency七ogive a greater release rate of bu七amben. These 
observations may be a七tributedto the fac七 thatthe surfactan七
either we七sthe membrane surface be七七eror promo七esdissolution 
79) of the drug'-'. The P value was therefore de七erminedin each 
case using a drug suspension containing a corresponding surfactan七.
工nFig. 21 are shown the resu1ts for bu七ambenin the presence 
of three types of surfactants. Data are presented by p10t七ing
-1n(1 -Mr/Mω) agains七七ime七 accordingto Eq. 16. Data thus 
treated gave approximately linear profiles as were expec七edfrom 
the mode1 introduced. Experirnen七aldata poin七sfit七edon theo-
retical lines fairly well. 
Two 0七hersurfac七ants，anionic and ca七ionic，were also 
employed to exarnine the applicabili七yof七hemodel七0 七hese
systems (Fig. 22). A fit similar to that in Fig. 21 was observed. 
Slight deviation frorn 七heoreticallines may be a七七ributedto 
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a certain error in de七erminingthe P value from suspension da七a
or七oan uniden七ifiedfac七orwhich was not taken in七oaccoun七
in the rnode1. 
Benzocaine， an ana10g of bu七amben，was also ernployed七0
七es七 theapplicabili七Yof the model. Benzocaine has a higher 
solubi1i七Yin wa七erand a lower par七ition七endency七osilicone 
mernbranes than butamben which was described previously. Fig. 23 
shows the re1ease profi1es of benzocaine in the presence of七wo
七ypesof surfactan七s. Theore七ica1and experimen七alprofiles 
coincided， indicating tha七七hedrug release in this case can 
be satisfactori1y described by Eq. 16. 
Fig. 24 represents da七aobtained wi七h 七hee七hylene-vinyl
ace七atecopolymer membrane which is also classified as a par七i-
tion mernbrane. Re1ease of butamben七hroughthe ethylene-viny1 
ace七atecopo1ymer rnembrane a1so fo11owed the theore七ica11ine. 
When a suspension is employed as a donor solu七ion，a disso-
1ution step is invo1ved as we11 as partition and diffusion s七eps.
工nsuch a drug as bu七arnbenwhich has a rather 1arge (membrane/ 
wa七er) partition coefficient， dissolution may become a rate-
determining step in sorne instances. 工fsuch be a case in the 
butamben-silicone membrane sys七em，a calcula七edP value from 
permeation s七udiesin the presence of suspensions may no七 repre-
sent a "true permeability". Slight deviation of七heobserved 
profile from七he七heore七icalprofile in七hebu七arnben-silicone
membrane system may be attributable， in par七， to this phenomenon. 
On the other hand， the permeation profile of butamben through an 
ethylene-vinyl ace七atecopolymer membrane and七ha七 ofbenzocaine 
mernbrane 
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七hrougha si1icone membrane can be adequate1y described by七he
rnodel (Figs. 23 and 24)， indicating七ha七 apartition-con七rolled
process is dorninant in七hesesystems. These observations may 
be rationalized in七hefollowing way. Since benzocaine has a 
lower par七itioncoefficien七七hanbutarnben and the e七hy1ene-vinyl
ace七a七ecopolyrner mernbrane has lower perrneability七hansilicone 
rnernbrane (5.04 X 10-6 crn2/sec， roughly， one ha1f) ， partition of 
the drug in七othe rnernbrane rnay becorne a rate-lirni七ings七epin 
these two cases. 
From these results， the derived Eqs. 15 and 16 based on the 
proposed model shown in Fig. 4 are considered to adequa七ely
describe七herelease of drug through plane partition mernbranes 
frorn systems containing micelles. 
Thus far， considera七ionshave been on七hesys七ernsof drug 
permeation through membranes in a plane shee七 form. 工naddi七ion
to those systems， a system where the drug is re1eased 'through a 
capsu1ar (ho11ow cy1inder) membrane， which is ano七herpractical 
dosage form， was also analyzed. As presented in the sec七ionof 
THEORET工CALCONSIDERAT工ONS，an equa七ionwas derived which may 
describe the release profiles of the drug frorn solutions contain-
ing micelles in capsu1es (Eq. 18). 
工nFig. 25， release profi1es of butamben from capsules (type 1) 
in the presence of 5 and 15も sodiumdodecy1 su1fa七eare shown 
along with七heore七ica1curves predic七edfrom Eq. 18. 工n 七he
theoretical ca1culations， the fo11owing parame七erswere used: 
P = 1.2 X 10-5 crn2jsec， h = 3.1 cm， Cso = 1.7 ~ 10-6 rnoles/cm3 
at 370， V = 1 cm3， ro/ri = 9.5/6.4， and Cs = 1.05 メ 10ー 匂 and 
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Flgure 25. Release profiles of butamben from micel1ar 
sys七emsa七 adrug loading of 15.5 mg in 5も(0) and 15も
( 0) sodium dodecy1 sulfa七esolutions， in capsule七ype1 
at 37ぺ一一・一一， theore七icalprofi1es predic七edfrom Eq. 18. 
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2.9 x 10-匂 rno1es/crn3 in 5 and 15も sodiurndodecy1 sulfate solutions， 
respec七ively (deterrnined a七 370)，and M 00 = 15. 5 rng (loaded drug) . 
As is seen in七hefigure， experirnenta1 da七ashowed slower release 
ra七ethan is predicted theore七ically. The following in七erpre七a-
tions may be made. 
工nthe permeation experiments using七hediffusion cells， 
solu七ionsin both compar七men七swere effec七ive1ystirred so that 
七he七hicknessof a diffusion layer on七hesurface of七hemernbrane 
is rninirnized and a concen七ra七iongradien七 iskept constant. 
工n 七hepermeation experirnents using capsules， on七heother hand， 
the donor (i.e. in七racapsular) solu七ioncan not be s七irredmechan-
ica11y. Therefore， a contribu七ionof a diffusion layer七0 七he
78) 
七o七alrelease process may become apparen七. A poor correla七ion
of七heobserved data wi七htheoretical profiles in Fig. 25 may be 
due， in part，七0 七hediffusion-layer effect. 
工nFig. 26 are shown七hesarne experirnen七aldata as七ha七 in
Fig. 25 but with theoretical profi1es predicted from Eq. 15. 
工n 七hetheore七icalcalculations，七hefol1owing parame七erswere 
used: 1 = 0.155 cm (七hicknessof the capsu1e wa11) ， A = 6.25cm2 
(inner surface area of the capsule)， P， Cso， Cs， and V were the 
sarne as in the previous calcula七ions. The observed da七aand 
七hetheoretical profi1es coincided. Therefore， in this case， 
ana1ysis of七here1ease profi1es on the basis of Eq. 15 gave a 
satisfac七oryapproxirnation. The possib1e application of Eq. 15 
to the capsular systems was further examined. 
According to Eq. 15， Mr is expected to be propor七ionalto 
Mω・ Shownin Fig. 27 are七here1ease profi1es of butamben 
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Flgure 26. Re1ease profi1es of bu七ambenfrom mice11ar 
systemsat a drug 10ading of 15.5 mg in 5毛(0) and 15も
( 0) sodiurn dodecy1 su1fa七esolutions， in capsu1e type 1 
a七 37 0 •. ， theore七ica1profiles predic七edfrom Eq. 15. 
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七hreedrug loading levels a10ng wi七h theore七ica1curves predic七ed
from Eq. 15. 工n 七hiscase，. Cs = 2.27 x 10 匂 rno1esjcrn3 (so1ubi1-
i七yof bu七ambenin 10も sodiumdodecy1 su1fa七esolution a七 300) • 
The observed profi1es were very c10se to the curves theore七ica11y
drawn and七hedependency of Mr on M~ is apparent. The pararne七er
P is dependen七 on七hepolymeric ma七eria1，whi1e A， 2 and V are 
dependent on七hesize of the device used. When M~ and these 
parame七ersare fixed，七here1ease profi1e of七hedrug can be 
modified by the Cs terrn. A sys七ernhaving a 1arge Cs value may 
be regarded as a 1arge reservoir which functions七o sustain the 
drug re1ease. 工tis expected from Eq. 15七ha七 doub1ingthe 
value of Cs， for examp1e， wou1d lead to a two-fold increase in 
七he七imerequired to re1ease the same amoun七 ofdrug. The mag-
nitude of Cs can be increased by increasing the concen七ration
????、 ????? ?。???? ???? ????????????????。???????????????????????。
七hedrug more efficient1y. 
Shown in Fig. 28 is the effect of the surfactant concen-
tration on drug re1ease. Using the Cs va1ues in 5， 10， and 15も
sodium dodecyl su1fate so1utions (previous1y shown in this sec-
七ion)， theore七ica1re1ease profi1es were drawn according七oEq. 1， 
and a 七heoretica1ha1f-life (七hetime required七ore1ease one 
half of the drug incorporated) was ca1culated for each case. 
ト
k p 
Ca1cula七edhalf-lives were 0.99， 2.14， and 2.74 days for the 5， 
? ? ?
??????
? ? ?
? ? ? ? ?
?
10， and 15も surfactan七 systerns，respective1y. Corresponding 
half-lives obtained from the data shown in Fig. 28 were 0.91， 
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Rlease profiles of the drug from slu七ionsof two surfactan七s
are compared in Fig. 29. Dodecyl七rime七hylarnmoniumchloride 
solubilized bu七ambenmore七hansodium dodecyl sulfa七eat an equal 
concen七ra七ion (15も， in this case). Ha1f-1ives ob七ainedfrom七he
data were 2.49 and 5.04 days for the sodium dodecyl sulfa七eand 
dodecyl七rime七hy1ammoniumchloride sys七ems，respec七ively. Thus， 
七hedrug release can be increasingly sus七ainedby increasing七he
concen七rationof surfac七an七sor by employing a surfac七antwi七ha 
higher solubilizing abili七y for七hedrug. 
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Flgure 29. Release profiles of butamben from mice11ar 
systems in 15も surfactantsolutions at a drug loading of 
48.3 mg in capsule七ype1 a七 370C. 0， dodecyl trimethyl-
ammonium chloridei a， sodium dodecyl sulfa七e.
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4. Summary 
Surfac七an七swere examined for their possible role in 
sustaining drug release七hrougha membrane. Three七ypesof 
surfactan七s: anionic， cationic， and nonionic surfac七an七swere 
investiga七edas七otheir solubilizing and release-sus七aininq
behavior toward bu七amben・Among七he七hreesurfactants， dodecyl-
trime七hylammoniumchloride， a ca七ionicsurfac七ant，showed an 
excellent release-sus七ainingability for the drug. 
A theoretical model was introduced to describe七heperme-
ation of drug七hroughmembranes from sys七emscontaining micelles. 
Taking dis七ribu七ionof drug between aqueous and micellar phases 
in七oaccount， an equa七ionwas derived which describes the perme-
ation profile of drug from the system. Applicability of the 
equation based on the proposed model was experimentally tes七ed
employing benzocaine as well as butamben， one of five surfactan七s，
and silicone or e七hylene-vinylaceta七ecopolymer membrane. 
A fairly good agreement was obtained between the七heore七ical
values and experimen七aldata. -Thus， the derived equation has 
proved to adequately describe七hedrug release from the sys七em.
It was concluded that micelles serve as a large reservoir 
of drug and that the drug release can be increasingly sustained 
by increasing the concentra七ionof surfac七antsor by employing 
a surfactant with a higher solubilizing abili七yfor 七hedrug. 
A desired release profile of drug can， therefore， be achieved 
by se七七ingparameters properly on the basis of the model intro-
duced. The possible application of surfac七an七s七o sus七ained-
release systerns was indicated. 
PART工V: RELEASE OF BUTAMBEN FROM COSOLVENT SYSTEMS 
46 ) 1. So1ubi1ization of Butamben in Coso1ven七 Sys七ems
Shown in Fig. 30 is七hes01ubi1ity diagram of butamben in 
七hemacrogo1 400-water mix七ure. The s01ubi1ity of butamben was 
enhanced remarkab1y by an increase in the macrog01 frac七ionand 
七hesemi10gari七hrnicp10七 gavea s七raigh七 1inewhich is in con-
sistent wi七htha七七heore七ica11ypredicted by Eq. 19 (see experi-
mental sec七ion). For七hemacrogo1 frac七ionup to 0.5， the solu-
bi1i七yof butamben can be described by a specific form of Eq. 19 
using Cs 0 = 1. 7 mM = 1. 7 x 10 -6 mOles/cm3 (so1ubili七Yof butamben 
in water a七 370) and σ= 3.445 mo1es (s10pe of the 1ine in Fig. 30): 
10g Cs' = 10g (1.7 X 10-6) + 3.445・f (Eq. 29) 
where Cs' =七heso1ubi1ity of bu七ambenin the binary solvent of 
七heW/V fraction f of macrogol 400 a七 37 0 • This system is con-
sidered七opossess a reservoir func七ionfor the drug because of 
the increased solubili七Y of the drug. 
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and七hew/v fraction of macrogol 400 a七 37 0 •
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3. Summary 
Cosolvent systerns， rnacrogol 400-water rnix七ures，were eval-
ua七edfor七heirpossible use as drug reservoirs to con七rolor 
七osustain the drug release through a rnernbrane. The solubility 
of butamben was increased exponentially wi七h 七hecosolven七
(macrogol) frac七ion. The frac七ionalrelease ra七eof bu七amben
七hrougha silicone capsular mernbrane decreased linearly with七he
cosolven七 frac七ion. Thus，七herelease of bu七ambenwas rnore 
sustained by employing a vehicle (solven七 mixture) of higher 
frac七ionsof the cosolven七. Because of the high s七abili七yand 
solubilizing ability for the drug，七hecosolvents may be conve-
niently applied for the con七rolledand sustained drug release 
systems. 
46) PART V: RELEASE OF BUTAMBEN FROM 0工Lー工N-WATERTYPE EMULS工ON
The physical s七abilityof several preparations was investi-
gated prior to the release studies. Various degrees of phase 
separation were observed in a 5-day period in七heemulsions with 
low conten七sof sodium a1ginate and oils. The emu1sion prepared 
with 0.5 m1 of the oil con七aining48.3 rng of七hedrug and 0.5 ml 
of aqueous solu七ioncontaining 0.4毛 po1ysorbate80 and 2.0も sodium
algina七edid not show any noticeable phase separation in 5 days. 
The re1ease of butamben from this emulsion was exarnined and 
七heresul七sare shown in Fig. 35. The release pattern (so1id line) 
was almost the same as七ha七 obtainedwhen七hemicellar solu七ion
of 15も sodiumdodecyl su1fa七ewith七hesarne drug 10ading was 
used (dotted line). In emu1sions， much drug can be incorporated 
into七heoil phase so七ha七 asus七ainedre1ease is achieved. 
工nthis experiment， the size of the oil droplets in the 
formu1ated emulsion was no七 measured. 工fpermeation七hroughthe 
membrane is七heslower process， and hence the ra七e-de七er1Ilining
s七ep，七herelease ra七eis not expected to be influenced by drop-
let sizes. Although this assumption may have七obe examined 
when emu1sion droplets of 1arger sizes are emp1oyed. Since 
emulsions are physical1y unstable in contrast wi七hmicellar 
solutions or cosolvent systerns， its applicability to a general 
use rnay be limited. 
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Flgure 35. Comparison of七herelease profile of bu七amben
from the emulsion system (solid line) with that frorn七he
micellar sys七emin 15も sodiumdodecyl sulfate solution 
(do七七edline) a七 a drug loadinglevel of 48.3 mg in capsule 
type 1 at 37 0 • The emulsion was formulated wi七h 0.5 rnl of 
cotton seed oil con七ainingthe drug and 0.5 ml of an aqueous 
s01u七ioncon七aining0.4も polysorbate80 and 2.0も sodiurn
a1ginate. 
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PART V工: CORRELAT工ONOF RELEASE PROF工LES工NV工TRO
46) 
W工THRELEASE DATA工NV工VO
工ndeveloping a sustained drug release system for a given 
drug，七hein vi七ro-invivo correla七ionof bo七h 七hemechanisms 
and the ra七esof drug release should be evalua七ed. The informa-
tion七husob七ainedcan七henbe appllied to s七udies七ofurther 
develop a sys七ernthat delivers the drug at a programmed rate 
for an op七imumdura七ionof七rea七ment. As an initial evalua七ion
of七hesystems tha七havebeen described in the present work， 
release experiments in vivo were carried ou七.
工nFig. 36， the release of butamben from capsules implan七ed
subcutaneously in rabbits is shown together wi七hrelease data 
in vitro. Correlations of drug release from七opicaldelivery 
systems in vitro wi七h 七ha七 invivo have been repor七ed: sorne of 
81-84) which are good， some are poorU.-U~1 .工nspite of sorne possib1e 
differences be七ween七heenvironmen七ssurrounding the capsules 
in the in vitro and in vivo experirnen七s，a very close agreernent 
was found in七herelease ra七esbe七weenthe two s七udies. 工norder 
to compare these quantitatively，七hedata were analyzed on七he
basis of Eq. 16. 
A plot of ベー1- (Mr!叫叩ins七 timeshould give a 
straigh七 linewith a slope of APCso/1VCs. The slope thus obtained 
was used to cornpare七herelease pa七tern. The da七afor release 
studies in vi七roand in vivo are shown in Fig.37. 工nboth cases， 
straight lines with similar s10pes (1.60 X lO-6/sec in vitro， 
1.63 X 10-6/sec in vivo) were obtained. No significan七 difference
was found in the release profile of butamben frorn si1icone rubber 
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Flgure 35. Comparison of七herelease profile of bu七amben
from七heemulsion system (solid line) with that from the 
mice11ar system in 15も sodiumdodecyl sulfate so1u七ion
(dotted line) at a drug loading 1evel of 48.3 mg in capsule 
type 1 at 37 0 • The emulsion was formulated wi七h 0.5 ml of 
cotton seed oi1 containing the drug and 0.5 ml of an aqueous 
so1ution con七aining0.4も polysorbate80 and 2.0毛 sodium
alginate. 
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46) 
W工THRELEASE DATA工NV工VO
工ndeveloping a sus七aineddrug release sys七emfor a given 
drug， the in vitro-in vivo corre1ation of both七hernechanisms 
and the ra七esof drug re1ease shou1d be eva1uated. The informa-
七ionthus ob七ainedcan then be app11ied to s七udies七o fur七her
develop a sys七emthat delivers七hedrug a七 aprogrammed ra七e
for an op七imumduration of七rea七men七. As an ini七ialevalua七ion
of the systems that have been described in七hepresen七 work，
re1ease experimen七sin vivo were carried ou七.
工nFig. 36， the release of butamben from capsules imp1an七ed
subcu七aneous1yin rabbits is shown together wi七hre1ease data 
in vitro. Correlations of drug release from topica1 de1ivery 
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differences between the environmen七ssurrounding七hecapsu1es 
in the in vitro and in vivo experiments， a very c10se agreernen七
was found in the re1ease ra七esbetween the two s七udies. 工norder 
to compare these quan七itative1y，the data were ana1yzed on the 
basis of Eq. 16. 
A p10t of ベー1- (Mr/叫叩insttirne should give a 
s七raight1ine with a slope of APCso/1VCs. The slope thus obtained 
was used七ocompare七herelease pattern. The da七afor re1ease 
studies in vi七roand in vivo are shown in Fig.37. 工nboth cases， 
s七raightlines with similar s10pes (1.60 X 10四 6/secin vitro， 
1.63 X lO-6/sec in vivo) were obtained. No significan七 difference
was found in七herelease profi1e of butarnben from silicone rubber 
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Flgure 36. Comparison of the release profile of butamben 
from七hemicellar sys七emin 15毛 dodecyl七rime七hy1arn.rnoni um 
ch10ride solution at a drug loading leve1 of 48.3 mg in 
capsu1e七ype1. ・I in vitro a七 37勺 0，in vivo. 
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capsules be七weenthe七wos七udies. Al七houghrelease s七udies
in vivo were investigated only for七hernicellar sys七em，the 
close agreemen七 between七herelease in vi七roand in vivo would 
also be expected for the other systems included in七hiswork， 
since permeation through the silicone rubber membrane appeared 
七obe七hera七e-limitingstep and no accumula七ionof七hereleased 
drug around七hecapsule would be expec七ed.
Cornparative studies indica七ed七ha七七hedrug release in vitro 
agrees well with that observed in vivo. Therefore， an ini七ial
design of acon七rol1edrelease device may be made on七hebasis . 
of in vi七roexperiments. 
CONCLUD工NGREMARKS 
Controlled drug delivery systems have widely received 
a七七en七ionsfor 七heirpromising developmen七 in drug 七herapy.
Several systems developed七odate have found七heirpreferable 
use in七itra七ingdiseases more effec七ivelyover conventional 
methods， al七hough七heyare still open七ofurther improvemen七.
One of the most accesible and promising stra七egyfor the sys七ems
is the use of polymeric substances. Since polymers have a 
varie七yof charac七eris七icsand are capable of (physico-)chemical 
modifications，七heirlimitless use is expected. 
When a drug delivery sys七emusing polymers is considered， 
a proper choice of a drug， a polymer substance as well as geom-
etry of七hesystem is essential七oachieve a desired drug delivery. 
工n 七hestudies presented herein， possible con七rolof drug release 
through a polymer membrane by means of "solu七ionreservoir" of 
七hedrug was introduced and evalua七edfor i七sapplicabili七y.
Solub1e complexes of the drug， micelles， coso1vents， and oil-in-
water七ypeemulsions were examined for their reservoir functions 
to con七ro1or sustain the re1ease of 10cal anesthe七icsthrough 
silicone membranes. 
From the results obtained in the present inves七iqa七ions，
七hefollowing conclusions can be drawn: 
1) Among the local anesthetics exarnined， butamben is a good 
choice in the systems in which a partition membrane such as a 
silicone mernbrane plays a role of a release-ra七e-limi七ingbarrier. 
2) If systems are capable of forming soluble， membrane-imperme-
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ab1e comp1exes， the release of七hedrug frorn七hesystems can be 
sustained than七hatfrom the p1ain solu七ionof七hedrug， al七hough
never exceeding七hatfrom七hesuspension in wa七er. Control of 
the release profile of drug be七ween七heselimi七sis possible 
by means of a proper choice of complexing agents. The more 
stable七hecomplex is， the slower is七heinitial ra七eof release 
bu七七helonger is the七irnerequired for comple七erelease. 
3) Surfac七antsolu七ionscan retain drugs in solu七l.on七oa 
great ex七en七 dueto micellar solubilization and七husserve as a 
large reservoir of the drug. Grea七errelease ra七eand longer 
duration of re1ease can be achieved by a proper se1ection of 
surfac七an七s. Release profi1es of the drug from七hesys七ems
can be adequa七elydescribed quanti七atively，hence， predictable. 
4) Cosolvents also provide solution reservoir sys七ems，and 
cosiderably sustained release of the drug is obtained when 
cosolven七 systemswi七hlarge fractions of七henonaqueous cosol-
vent are employed. 
5) In emu1sions， much drug can be incorpo士a七edin七othe oi1 
phase so七hatsustained release is obtained. The general use of 
emulsions may be limited because of七heirpoor physical s七abil-
ity. 
6) Compara七ivestudies indicated七ha七七hedrug release in vitro 
agrees well with that observed in vivo. Therefore， an initial 
design of a controlled release device may be made on the basis 
of in vitro experiments. 
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Thus，七hosesolution reservoir systems described can be 
usefully applied to the drug delivery sys七emsin combina七ion
with a proper choice of a drug or a membrane ma七erialas well as 
a geome七ryof the sys七em.
SCOPE 
In the present work， a silicone rubber membrane was selected 
as a release-rate-limiting barrier for the drug. Becaus~ of the 
wel1 documented biocompatibility， silicones are being widely used 
for medical purposes. For example， silicones are used in artificial 
lungs， heart valves， pace-makers， and other artificial organs. 
If necessary， drugs can be impregnated in the polymer from which 
they are released to exert antiinflammatory， antiinfective or 
immunosuppresive actions. 
A silicone elastmer is classified as a "biostable" polymer. 
The elastmer is less susceptible to any chemical and/or physical 
changes. More recently， biodegradable polymers have been intro-
duced to the drug delivery systems. Fol1owing a hydrolytic or 
enzymatic degradation of the polymers containing drugs within the 
body， concomitant drug release can be obtained. Such systems 
should be prepared from toxicological1y acceptible components. 
The means for sustaining release of drugs as those described 
in the present work may be extended to the biodegradable drug 
delivery systems which are composed of biodegradable polymers， 
toxicologically acceptible additives such as natural surfactants， 
and the drug. 
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